https://www.bioworld.com/rss en-us Beta Pharma Inc. has disclosed antibody-drug conjugates consisting of humanized monoclonal antibody trastuzumab targeting receptor tyrosine-protein kinase erbB-2 (erbB2; HER2) covalently linked to cytotoxic drug through a cleavable linker reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/733062 Thu, 30 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733062-beta-pharma-identifies-new-her2-targeting-adcs Iksuda Therapeutics Ltd. has obtained IND clearance from the FDA for IKS-04, enabling initiation of a phase I trial in patients with gastrointestinal cancers. http://www.bioworld.com/articles/733052 Thu, 30 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733052-iksudas-iks-04-gains-ind-clearance-for-gastrointestinal-cancers Illustration of esophagus, liver, stomach, intestines Researchers from Jacobio Pharmaceuticals Co. Ltd. recently presented preclinical data on JAB-BX600, an EGFR-directed antibody-drug conjugate (ADC) that selectively delivers a KRAS G12D inhibitor to tumor cells, allowing dual inhibition of the EGFR-KRAS pathway. http://www.bioworld.com/articles/733000 Wed, 29 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733000-jab-bx600-shows-promise-in-kras-g12d-cancers Promatix Biosciences Ltd. has been awarded an Innovate UK Biomedical Catalyst grant to support development of its lead program, PBS-293-exatecan, a first-in-class EGFR x EphA2 cis-bispecific antibody-drug conjugate. http://www.bioworld.com/articles/732979 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732979-promatix-advances-pbs-293-exatecan-with-innovate-uk-grant Colon cancer illustration Veraxa Biotech AG has reported the advancement of its bispecific antibody-drug conjugate (bsADC) program VXA-222, following achievement of a technical milestone in its alliance with Omniab Inc. The program is moving into its next collaboration phase. http://www.bioworld.com/articles/732960 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732960-veraxa-biotech-advances-bispecific-adc-from-omniab-collaboration 3D rendering of a drug capsule and flying antibodies Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. said its IND application was approved in China for SKB-565, its dual-payload antibody-drug conjugate (ADC), for the treatment of advanced solid tumors. http://www.bioworld.com/articles/732959 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732959-kelun-biotechs-skb-565-cleared-to-enter-clinic-in-china Antibody-drug conjugate illustration Bioray Pharmaceutical Co. Ltd. has prepared and tested new antibody-drug conjugates consisting of antibodies covalently linked to payloads. They are reported to be potentially useful for the treatment of cancer, infections, inflammatory and immunological disorders. http://www.bioworld.com/articles/732910 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732910-antibody-drug-conjugates-reported-in-bioray-pharmaceutical-patent Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer. http://www.bioworld.com/articles/732908 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732908-hengrui-synthesizes-new-adcs-targeting-ceacam5 Shanghai Escugen Biotechnology Co. Ltd. has disclosed new antibody-drug conjugates comprising chimeric monoclonal antibodies targeting CD174 (Lewis y) covalently linked to a cytotoxic drug. They are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732889 Thu, 23 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732889-shanghai-escugen-biotechnology-patents-adcs-targeting-cd174 Mediboston Biologics Co. Ltd. has disclosed new antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to a camptothecin derivative potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732819 Tue, 21 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732819-mediboston-biologics-patents-new-antibody-drug-conjugates Akari Therapeutics plc has established a strategic research collaboration with Whitehawk Therapeutics Inc. to conduct preclinical studies evaluating Akari’s proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor antibody-drug conjugate platform. http://www.bioworld.com/articles/732803 Tue, 21 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732803-akari-and-whitehawk-collaborate-on-adc-research Scientists shaking hands in the lab Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In preclinical models of HER2 and EGFR co-expressing pancreatic, breast and gastric tumors, sequential administration of the ADC and the second antibody was better at shrinking tumors than either ADC monotherapy or a combination of antibody and ADC treatment. http://www.bioworld.com/articles/732802 Mon, 20 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732802-in-vivo-click-adcs-could-address-tumor-heterogeneity Click chemistry drug bound to pancreatic cancer cells from mice WashU Medicine researchers show in mice that their technique to designing medications, in which modular components of anticancer drugs are administered separately and assembled in the body using what's known as click chemistry, is more effective than standard treatments at targeting and shrinking tumors. Shown is a drug they designed, labeled in pink and green, bound to pancreatic cancer cells from mice. Credit: Shayla Shmuel Eioncell Co. Ltd. and Hallym University have reported new antibody-drug conjugates (ADCs) comprising an antibody targeting kita-kyushu lung cancer antigen 1 (KK-LC-1; CT83) linked to a cytotoxic drug potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732719 Fri, 17 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732719-eioncell-and-hallym-university-patent-ct83-targeting-adcs Shanghai Henlius Biologics Co. Ltd., Shanghai Henlius Biopharmaceutical Co. Ltd. and Shanghai Henlius Biotech Inc. have disclosed new antibody-drug conjugates comprising a monoclonal antibody targeting HER2 covalently linked to a camptothecin derivative potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732684 Thu, 16 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732684-henlius-patents-new-her2-targeting-adcs Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer. http://www.bioworld.com/articles/732500 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732500-grant-supports-rybodyns-antibody-therapies-for-lung-cancer Lung cancer illustration A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC). http://www.bioworld.com/articles/732495 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732495-beijing-mabworks-biotech-discloses-new-dll3-targeting-adcs Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and more potent class of payload. With the first two programs due to enter clinical development before the end of the year, the Swiss pharma also will pay up to $400 million more in potential milestones. The centerpiece of the deal is London-based Myricx’s N-myristoyltransferase inhibitors, which in preclinical testing have prompted complete and durable tumor regression at well-tolerated doses in a range of solid tumors. http://www.bioworld.com/articles/732468 Tue, 07 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732468-novartis-to-pay-15b-for-myricx-bio-and-its-novel-adc-payloads 3D rendering of antibody drug conjugated with cytotoxic payload Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma Inc./Pfizer Inc.), and possibly to ADCs more broadly. Urothelial cancer drug Padcev, which targets the cell adhesion molecule Nectin-4, was approved in 2019 and is currently one of Pfizer’s top 10 medicines and vaccines, generating $1.94 billion in 2025. http://www.bioworld.com/articles/732450 Tue, 07 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732450-target-high-but-uptake-defective-state-identified-in-adc-resistance 3D rendering of an antibody-drug conjugate The April 2024 full U.S. FDA approval of Pfizer Inc. and Genmab A/S’ tissue factor-targeting antibody-drug conjugate Tivdak (tisotumab vedotin) for cervical cancer sparked interest from drug developers in the strategy, which has been known about for a while. http://www.bioworld.com/articles/732286 Mon, 06 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732286-post-tivdak-research-in-tissue-factor-multiplies Tivdak Credit: Business Wire Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and more potent class of payload. With the first two programs due to enter clinical development before the end of the year, the Swiss pharma also will pay up to $400 million more in potential milestones. The centerpiece of the deal is London-based Myricx’s N-myristoyltransferase inhibitors, which in preclinical testing have prompted complete and durable tumor regression at well-tolerated doses in a range of solid tumors. http://www.bioworld.com/articles/732285 Mon, 06 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732285-novartis-to-pay-15b-for-myricx-bio-and-its-novel-adc-payloads 3D rendering of antibody drug conjugated with cytotoxic payload Children’s Hospital of Fudan University, Sydney Children’s Hospital and the University of Sydney have jointly patented new antibody-drug conjugates comprising an antibody targeting GD2 ganglioside covalently linked to cytotoxic drugs potentially useful for the treatment of osteosarcoma. http://www.bioworld.com/articles/732411 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732411-chinese-australian-researchers-disclose-gd2-ganglioside-targeting-adcs Salubris Biotechnology Co. have reported the development of novel antibody-drug conjugates (ADCs) against glypican-3 (GPC3), an oncofetal glycoprotein overexpressed in approximately 70%-85% of hepatocellular carcinoma (HCC) cases but absent in normal adult tissues. http://www.bioworld.com/articles/732189 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732189-gpc3-targeting-adc-for-hcc-shows-superior-efficacy-in-preclinical-models Missing statistical significance on the primary overall survival phase III endpoint with antibody-drug conjugate (ADC) sigvotatug vedotin compared with docetaxel in non-small-cell lung cancer (NSCLC), Pfizer Inc., which gained the candidate through its $43 billion buyout of Seagen Inc. in 2023, is forging ahead based on subgroup signals, phase I data and an ongoing phase III Keytruda combination effort currently underway. http://www.bioworld.com/articles/732060 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732060-pfizer-adc-from-seagen-m-and-a-fails-in-phase-iii-nsclc-trial Lung cancer illustration MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732152 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732152-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732123 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732123-rin-institute-discovers-new-insoluble-fibrin-targeting-adcs MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732090 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732090-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732019 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732019-sichuan-kelun-biotech-biopharmaceutical-patents-new-heterocyclic-compounds A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer. N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.]]> http://www.bioworld.com/articles/731971 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731971-hengrui-pharmaceuticals-prepares-new-adcs-for-cancer Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or antigen-binding fragments targeting V-set domain-containing T-cell activation inhibitor 1 (VTCN1, B7-H4) and tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to cytotoxic drug. They are described as potentially useful for the treatment of cancer. http://www.bioworld.com/articles/731868 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731868-fortvita-and-innovent-patent-new-anti-trop2-b7-h4-adcs Shanghai Ruotuo Biotechnology Co. Ltd. has patented antibody-drug conjugates (ADCs) comprising bispecific antibodies targeting epidermal growth factor receptors (EGFR; ERBB; HER) and receptor tyrosine-protein kinase erbb-3 (ERBB3; HER3) linked to a cytotoxic drug through a linker intended for use in the treatment of cancer. http://www.bioworld.com/articles/731865 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731865-shanghai-ruotuo-biotechnology-discovers-new-anti-egfr-her3-adcs